Board of Directors

Kal Chatto

Mr. Kal Chatto served Amgen Inc for over sixteen years in several leadership capacities including Marketing and Training and Medical Affairs. He has the credit of being recruited from Glaxo Inc. Senior Management Team in 1988 to be one of the first 9 Amgen business development and commercialization executive leaders.

With 24 years of experience in the Pharmaceutical and Biotech Field, Mr. Chatto has the distiction of contributing to the success of Amgen in making it the one of the best biotech companies worldwide. He is also on the board of leading professional organizations and key pharmacy schools of prestigious U.S Universities.

Mr. Kal Chatto received his B.Pharm from Banaras Hindu University and M.S. in Pharmacy Administration from the Long Island University, New York. He has also completed the Executive Management Programs from the Marshall School of Business, USC and the Anderson School of Management, UCLA.

Chuck Scott, Ph.D.

Dr. Chuck Scott is a biological scientist by training and has spent the last thirty years as the CEO of CBS Scientific.  Dr, Scott earned a BS with Honors from the University of California, San Diego.  He was awarded a Ph.D. in Biology from UCSD in the area of cell mediated immunity to virus induced tumors.  During his post-doctoral fellowship, he founded CBS Scientific.  Since founding the company in 1980, he has been the CEO and chief scientific officer for CBS Scientific.  Holder of several patents on electrophoresis separation of biological macromolecules, Dr. Scott’s firm manufactures components used in automated sequencing equipment for several instrumentation firms.

Ajai Khanna, M.B.B.S, Ph.D., MBA, FRCS., FACS

Dr. Ajai Khanna is a leading transplant surgeon and researcher who specializes in multi-organ transplantation, liver and small bowel transplantation in children, and pancreas transplantation. As Director of the UCSD-Children’s Hospital Pediatric Abdominal Transplant Program, he performs complex and innovative transplant surgeries for young patients, such as the living related liver transplant in which a child receives part of a parent’s liver to replace the child’s own diseased liver. Dr. Khanna is certified in multi-organ transplantation by the American Society for Transplant Surgeons. He is also certified in General Surgery by the Royal College of Surgeons of England and the Specialist Training Authority of the General Medical Council of the United Kingdom.

Dr. Khanna was the first surgeon in the world to perform “domino” liver transplantation in a patient with Maple Syrup Urine Disease and a patient with liver cancer.  Dr. Khanna was also the first surgeon in San Diego to perform multi-visceral transplantation and also the first to perform live donor liver transplantation in San Diego. Dr. Khanna started and established the Pediatric Abdominal Transplant Program at the University of California, San Diego and Children’s Hospital and Health Center.
In addition to his surgical and specialty training, Dr. Khanna has advanced fellowship training in general surgery, multi-organ transplant surgery, multi-organ pediatric abdominal transplantation and transplant immunology.

In his patient care and teaching activities, Dr. Khanna works closely with the specialists in transplant surgery, general surgery, hepatology, nephrology, critical care, pediatrics, pediatric gastroenterology and pediatric nephrology. He is a member of the Moores UCSD Cancer Center, where he provides specialized surgical care for patients with liver cancers.

Dr. Khanna is active in training new specialists in transplantation at UCSD. He heads the Department of Surgery’s fellowship training program in multi-organ transplant surgery, and has mentored and trained transplantation surgeons from around the world.Dr. Khanna devotes his research to developing methods for improving the success and safety of organ transplants. He is recognized for his research on artificial liver and bone marrow augmentation of organ tolerance. His current studies include investigations of anti-rejection drugs and the prevention of reinfection in hepatitis B-related transplants. He is involved in a number of clinical trials, including a study of split liver transplantation to improve organ viability in children.